ClinicalTrials.Veeva

Menu

Descartes-11 in Multiple Myeloma

C

Cartesian Therapeutics

Status and phase

Active, not recruiting
Phase 2
Phase 1

Conditions

Multiple Myeloma

Treatments

Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Descartes-11

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

This Phase I/2 study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.

Enrollment

25 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Active multiple myeloma that is refractory after at least 2 prior lines of therapy;
  • measurable disease;
  • adequate vital organ function; and
  • no active infection.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

25 participants in 1 patient group

Dose-Escalation
Experimental group
Treatment:
Drug: Fludarabine
Biological: Descartes-11
Drug: Cyclophosphamide

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems